Posttraumatic stress disorder therapeutics (ptsd) pipeline assessment and market forecasts to 2019

Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment andMarket Forecasts to 2019GlobalData, the industry analysis specialist, has released its new report, “PosttraumaticStress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019”.The report is an essential source of information and analysis on the global Post-TraumaticStress Disorder (PTSD) Therapeutics market. The report identifies the key trends shapingand driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. Thereport also provides insights on the prevalent competitive landscape and the emergingplayers expected to significantly alter the market positioning of the current market leaders.Most importantly, the report provides valuable insights on the pipeline products within theglobal Post-Traumatic Stress Disorder (PTSD) Therapeutics sector. This report is builtusing data and information sourced from proprietary databases, primary and secondaryresearch and in-house analysis by GlobalData’s team of industry experts.Get more information of this report @ http://www.reportsnreports.com/reports/167924-posttraumatic-stress-disorder-therapeutics-ptsd-pipeline-assessment-and-market-forecasts-to-2019.htmlReport Details:Published: June 2012No. of Pages: 87Price: Single User License: US $ 3995 Corporate User License: US $ 11985ScopeThe report provides information on the key drivers and challenges of the Post-Traumatic Stress Disorder(PTSD) Therapeutics market. Its scope includes -- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Post-Traumatic StressDisorder (PTSD) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.- Pipeline analysis data providing a split across the different phases, mechanisms of action beingdeveloped and emerging trends by seven key markets. Pipeline candidates fall under major therapeuticclasses.- Analysis of the current and future competition in the seven key countries Post-Traumatic StressDisorder (PTSD) Therapeutics market.- Insightful review of the key industry drivers, restraints and challenges. Each trend is independentlyresearched to provide a qualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization, unmet needs andthe implications for the Post-Traumatic Stress Disorder (PTSD) Therapeutics market.- Analysis of key recent licensing and partnership agreements in Post-Traumatic Stress Disorder (PTSD)Therapeutics marketReasons to buyThe report will enhance your decision making capability. It will allow you to -- Develop and design your in-licensing and out-licensing strategies through a review of

pipeline products and technologies and by identifying the companies with the most robustpipeline.- Develop business strategies by understanding the trends shaping and driving the globalPost-Traumatic Stress Disorder (PTSD) Therapeutics market.- Drive revenues by understanding the key trends, innovative products and technologies,market segments and companies likely to impact the global Post-Traumatic Stress Disorder(PTSD) Therapeutics market in future.- Formulate effective sales and marketing strategies by understanding the competitivelandscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effectivecounter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories andsegments that present maximum opportunities for consolidations, investments andstrategic partnerships.- What’s the next big thing in the global Post-Traumatic Stress Disorder (PTSD)Therapeutics market landscape? – Identify, understand and capitalize.Major points covered in Table of Contents of this report include:Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Posttraumatic Stress Disorder Therapeutics - Introduction 82.1 Disease Overview 82.2 Epidemiology 92.2.1 Prevalence 92.2.2 Pharmacoeconomic Burden 112.2.3 Quality of Life (QoL) 122.3 Etiology and Pathophysiology 122.3.2 Risk Factor 182.3.3 Co-morbidities 192.4 Signs and Symptoms 202.4.1 Re-experiencing Symptoms 202.4.2 Avoidance symptoms 202.4.3 Hyperarousal Symptoms 202.5 Diagnosis 222.5.1 Diagnosis Criteria 222.5.2 Psychobiologic Approaches 252.6 Treatment and Management Options 262.6.1 Non-pharmacological Treatment 282.6.2 Pharmacological Treatment 282.6.3 The US 312.6.4 Europe 322.7 Referral Pathway 332.8 GlobalData Pipeline Report Guidance 343 Posttraumatic Stress Disorder Therapeutics - Market Characterization 35

3.1 Overview 353.2 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Global 353.3 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Global 373.4 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - The US 383.5 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - The US 393.6 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - France 403.7 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - France 413.8 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Germany 423.9 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Germany 433.10 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Italy 443.11 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Italy 453.12 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Spain 463.13 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Spain 473.14 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - The UK 483.15 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - The UK 493.16 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Japan 503.17 PTSD Therapeutics Market Forecast (2011-2019) - Japan 513.18 Drivers and Barriers for the Posttraumatic Stress Disorder Therapeutics Market 523.18.1 Drivers for the Posttraumatic Stress Disorder Therapeutics Market 523.18.2 Barriers for the Posttraumatic Stress Disorder Therapeutics Market 523.19 Opportunity and Unmet Need Analysis 533.20 Key Takeaway 544 Posttraumatic Stress Disorder Therapeutics - Competitive Assessment 554.1 Overview 554.2 Strategic Competitor Assessment 554.3 Product Profiles for the Major Marketed Products in the Posttraumatic Stress Disorder TherapeuticsMarket 564.3.1 Selective Serotonin Reuptake Inhibitors (SSRIs) 564.3.2 Paxil (paroxetine) 574.3.3 Zoloft (sertraline) 584.3.4 Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) 594.3.5 Atypical Antipsychotics 604.4 Key Takeaway 605 Posttraumatic Stress Disorder Therapeutics - Pipeline Assessment 615.1 Overview 615.2 Strategic Pipeline Assessment 615.3 Posttraumatic Stress Disorder Therapeutics Pipeline - Pipeline by Phases of Development 625.3.1 Posttraumatic Stress Disorder Therapeutics - Phase III Pipeline 625.3.2 Posttraumatic Stress Disorder Therapeutics - Phase II Pipeline 635.3.3 Posttraumatic Stress Disorder Therapeutics - Phase I Pipeline 635.3.4 Posttraumatic Stress Disorder Therapeutics - Pre-clinical Pipeline 635.3.5 Posttraumatic Stress Disorder Therapeutics - Discovery Pipeline 645.3.6 Technology Trends Analytic Framework 645.4 Posttraumatic Stress Disorder Therapeutics Market -Pipeline by Mechanism of Action 665.5 Molecule Profile for Promising Drugs under Clinical Development 675.5.1 Avlocardyl (propranolol) 675.6 Key Takeaway 676 Posttraumatic Stress Disorder Therapeutics - Clinical Trials Mapping 686.1 Clinical Trials by Region/Country (US, EU5 and Japan) 68

6.2 Clinical Trials by Phase 696.3 Clinical Trials by Trial Status 706.4 Prominent Sponsors 716.5 Top Companies Participating in Posttraumatic Stress Disorder Therapeutics Clinical Trials 727 Posttraumatic Stress Disorder Therapeutics - Strategic Assessment 737.1 Key Events Impacting the Future Market 737.2 Posttraumatic Stress Disorder Therapeutics: Implications for Future Market Competition 748 Posttraumatic Stress Disorder Therapeutics - Future Players 758.1 Introduction 758.2 Company Profiles 768.2.1 Synosia Therapeutics/Biotie Therapies Corp. 768.2.2 Columbia Northwest Pharmaceuticals 778.2.3 Marinus Pharmaceuticals, Inc. 778.2.4 Nanotherapeutics, Inc. 789 Posttraumatic Stress Disorder Therapeutics - Licensing and Partnership Deals 7910 Posttraumatic Stress Disorder Therapeutics - Appendix 8010.1 Market Definitions 8010.2 Abbreviations 8010.3 Bibliography 8110.4 Research Methodology 8310.4.1 Coverage 8310.4.2 Secondary Research 8410.4.3 Forecasting 8410.4.4 Primary Research 8610.4.5 Expert Panel Validation 8710.5 Contact Us 8710.6 Disclaimer 87Related Reports @ http://www.reportsnreports.com/publisher/globaldata/Contact:TX, Dallas North - Dominion Plaza,17304, Preston Road,Suite 800, Dallas 75252.Tel: + 1 888 391 5441sales@reportsandreports.comConnect With Us:

Posttraumatic stress disorder therapeutics (ptsd) pipeline assessment and market forecasts to 2019

by ReportsnReports on Jun 22, 2012

Accessibility

Categories

Upload Details

Usage Rights

Statistics

Posttraumatic stress disorder therapeutics (ptsd) pipeline assessment and market forecasts to 2019 Document Transcript